Latest Breaking News On - Alexey aleshin - Page 1 : comparemela.com

Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications

Demonstrates commitment to generating real-world clinical evidence to change disease management and improve patient outcomes .

Natera, Inc. (NASDAQ:NTRA) Q4 2023 Earnings Call Transcript

Natera, Inc. (NASDAQ:NTRA) Q4 2023 Earnings Call Transcript February 28, 2024 Natera, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator […]

Nature Medicine Publishes Two Studies Highlighting Signatera's Clinical Utility in Patients with Gastrointestinal Malignancies -January 25, 2024 at 07:04 am EST

AMPLIFY-201, a phase I trial evaluating treatment response to the ELI-002 vaccine, is the first study to read out using ctDNA to enroll and monitor patients with solid tumors PANDA study shows.

Nature Medicine Publishes Two Studies Highlighting Signatera's Clinical Utility in Patients with Gastrointestinal Malignancies

Natera, Inc. (NASDAQ:NTRA) Q3 2023 Earnings Call Transcript

Operator: Thank you for standing by and welcome to the Natera Inc. Q3 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.